Sarepta Therapeutics (SRPT) News Today

Sarepta Therapeutics (NASDAQ: SRPT): Stock Decrease Driven by Gene Therapy Safety Concerns

• Negative Sentiment: Sarepta shares crashed about 37% after reports of a third patient death linked to its gene therapies and mounting FDA scrutiny. Sarepta Stock (SRPT) Crashes 37% as FDA Scrutiny Mounts Over Gene Therapy Deaths
• Negative Sentiment: The FDA is considering whether Elevidys should remain on the market after two teenage patients died, triggering a 30% plunge in shares. Sarepta shares plunge 30% as future of its gene therapy appears at risk
• Negative Sentiment: Sources say the FDA will ask Sarepta to voluntarily stop all shipments of Elevidys amid safety concerns. Exclusive: US FDA to request Sarepta to stop all shipments of gene therapy Elevidys
• Negative Sentiment: Several brokerages, including Baird, Needham, Bank of America and RBC, downgraded the stock or cut price targets, citing Elevidys safety issues and mortality reports.
• Neutral Sentiment: Trading in SRPT was halted twice due to Limit Up/Limit Down (LULD) pauses amid heightened volatility.
• Neutral Sentiment: Multiple law firms have filed or reminded investors of securities class action lawsuits against Sarepta related to alleged misstatements about its gene therapy safety, with lead plaintiff deadlines approaching.